FILTER BY TOPIC:     Enrollment   Pre-Clinical   First Dose   Phase 1   Phase 1/2   Phase 2   Phase 2/3   Phase 3  

Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt...

June 21
Last Trade: 1.34 0.05 3.89

Established Medium Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial DSMB Determination to Proceed with High Dose Cohort Dosing MALVERN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on...Read more

Gilead Sciences’ Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention

June 20
Last Trade: 69.87 1.38 2.01

First Phase 3 HIV Prevention Trial Ever to Show Zero Infections  Independent Data Monitoring Committee Recommended That Gilead Stop the Blinded Phase of the PURPOSE 1 Trial at Interim Analysis and Offer Open-Label Lenacapavir to All Participants  FOSTER CITY, Calif. / Jun...Read more

ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled...

June 20
Last Trade: 5.61 0.07 1.26

SOLANA BEACH, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner Aspen Neuroscience, Inc. on use of...Read more

Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes

June 21
Last Trade: 1.80 0.05 2.57

Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease Company Anticipates Six Month Review and Potential Launch in Early 2025 THE WOODLANDS, Texas, June 21, 2024 (GLOBE NEWSWIRE) -- Lexicon...Read more

Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of...

June 21
Last Trade: 1.25 0.10 8.69

DUBLIN, Ireland and CHICAGO, June 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community...Read more

Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately...

June 20
Last Trade: 148.64 0.86 0.58

Submission is supported by 48-week results from the Phase 3 GALAXI and GRAVITI programs TREMFYA® is the only IL-23 inhibitor to demonstrate strong endoscopic outcomes with subcutaneous (SC) induction, consistent with intravenous (IV) induction, and has the potential to be the first in its class...Read more

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is installed...


Biggest Gainers

CompanyChangeLast Trade
Sarepta Therapeutics 39.19 31.73 $162.69
Madrigal Pharmaceuticals 11.52 4.30 $279.32
argenx 9.90 2.55 $397.77
Regeneron Pharmaceuticals 9.51 0.91 $1,053.90
ZIVO Bioscience 6.75 613.64 $7.85
United Therapeutics 6.73 2.18 $315.71
Thermo Fisher Scientific 6.53 1.17 $563.75
Alnylam Pharmaceuticals 6.07 3.86 $163.47
Third Harmonic Bio 5.49 76.25 $12.69
Danaher 4.09 1.65 $252.65
Chemed 3.85 0.72 $537.29
ICON 3.01 0.95 $319.01
Prestige Healthcare 2.94 4.50 $68.22
Veradigm 2.69 39.50 $9.50
Avidity Biosciences 2.64 7.02 $40.25
Eli Lilly 2.61 0.29 $888.60
BeiGene 2.58 1.66 $158.12
Disc Medicine 2.45 5.94 $43.70

Highest Volume

CompanyVolumeLast Trade
Mustang Bio 62,545,067 $0.61
Nexalin Technology 41,281,782 $1.89
DermTech 37,208,754 $0.12
Sharecare 34,631,834 $1.37
Kintara Therapeutics 30,783,347 $0.27
Qualigen Therapeutics 24,971,283 $0.18
Clover Health 18,847,542 $1.29
Pfizer 17,519,001 $27.64
Gilead Sciences 12,432,616 $69.87
Ginkgo Bioworks 11,809,779 $0.41
ENDRA Life Sciences 10,082,002 $0.12
Sarepta Therapeutics 9,195,574 $162.69
NLS Pharmaceutics 7,981,653 $0.19
Gossamer Bio 7,438,691 $0.69
GeoVax Labs 6,749,002 $2.23
Bristol-Myers Squibb 6,263,535 $41.20
ReShape Lifesciences 5,731,601 $0.19
Roivant 4,877,128 $10.81
bluebird bio 4,814,837 $0.90
  • Upcoming FDA Catalysts

    • Sarepta Therapeutics (NASDAQ: SRPT) PDUFA Date

      June 21, 2024
    • Verona Pharma (NASDAQ: VRNA) PDUFA Date

      June 26, 2024
    • Protalix BioTherapeutics (NYSEAMEX: PLX) Data Presentation

      June 26, 2024
    • Arcutis Biotherapeutics (NASDAQ: ARQT) PDUFA Date

      July 7, 2024
    • Phathom Pharmaceuticals (NASDAQ: PHAT) PDUFA Date

      July 19, 2024
    • Humacyte (NASDAQ: HUMA) PDUFA Date

      August 10, 2024

Featured Stock


Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...


Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...


Featured Stock


Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....


Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...


Invest In Early-Stage Biotech Opportunities

  • Explore venture capital investment opportunities in the healthcare industry and gain direct access to deal flows

  • Private placement shares can generally be purchased at a discount to market prices and have purchase warrants attached to them

  • If the underlying share price rises, warrants can be exercised to further build positions and enhance gains

  • Sign up to receive notifications of future early-stage investment opportunities: